reSee.it Video Transcript AI Summary
Over a hundred members of Congress are backing a bill to fund Ozempic through Medicare at $1,500 monthly, many having received funds from Novo Nordisk, its manufacturer. Once Medicare approves, Medicaid follows. There's a push to prescribe Ozempic for obesity in Americans as young as six, a condition largely preventable. With 74% of Americans obese, covering Ozempic prescriptions would cost $3 trillion annually.
Novo Nordisk's value relies heavily on projected Ozempic sales in the US, yet Denmark, their home country, favors diet and exercise over the drug. For half the cost of Ozempic, we could provide regeneratively raised organic food to every American, three times a day, and gym memberships for every obese American. Why is Congress prioritizing this company over American well-being? I've dedicated my life to solving the childhood chronic disease crisis, and I see an opportunity for bipartisan change to improve American health, our economy, and our nation's spirit.